433
On 20/12/2007, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number 516. The active ingredient is recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3 for treatment of acute myeloid leukaemia.